Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002393 · ClinicalTrials.gov registry record · Phase 3
A Study of Indinavir Taken With or Without DMP 266
A Phase 3 study, sponsored by Dupont Merck.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00002393: Completed Phase 3 study, sponsored by Dupont Merck.
NCT00002393 is a Phase 3 study that has completed, run by Dupont Merck. The registered enrollment target is 300 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002393, a Phase 3 study, has completed, sponsored by Dupont Merck.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to add DMP 266 to an anti-HIV treatment program of indinavir and nucleoside reverse transcriptase inhibitors (NRTIs).
Interventions
- DRUG Efavirenz
- DRUG Indinavir sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002393
The ClinicalTrials.gov registry entry for NCT00002393 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dupont Merck, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Efavirenz is the first listed.
NCT00002393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002393 about?
NCT00002393 is a clinical study titled "A Study of Indinavir Taken With or Without DMP 266". The purpose of this study is to see if it is safe and effective to add DMP 266 to an anti-HIV treatment program of indinavir and nucleoside reverse transcriptase inhibitors (NRTIs).
What is the current status of trial NCT00002393?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants.
What interventions are being tested in trial NCT00002393?
The interventions under investigation include: Efavirenz (DRUG), Indinavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00002393?
This trial is sponsored by Dupont Merck, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.